Company Analysis
Sign in

Atea Pharmaceuticals, Inc. (AVIR)

Nasdaq: AVIR · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2013
Full chart Alerts Compare
Grade6.5
◀ Past 7.1● Present 7.6▶ Future 5.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

24 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Atea Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
24
24 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 4 in 2023
Applications published
39
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Atea Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
24 granted
36 published
Atea Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,458,656Advantageous anti-HCV combination therapyPharmaceuticalsAtea Pharmaceuticals, Inc.
Feb 18, 202512,226,429Highly active compounds against COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc.
Sep 10, 202412,084,473β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentOrganic fine chemistryAtea Pharmaceuticals, Inc.
Jun 11, 202412,006,340Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusPharmaceuticalsAtea Pharmaceuticals, Inc.
May 7, 202411,975,0162′-substituted-N6-substituted purine nucleotides for RNA virus treatmentPharmaceuticalsAtea Pharmaceuticals, Inc.
Nov 14, 202311,813,278Highly active compounds against COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc.
Aug 29, 202311,738,038Highly active compounds against COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc.
Jul 25, 202311,707,480Highly active compounds against COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc.
Jul 4, 202311,690,860Treatment of HCV infected patients with cirrhosisPharmaceuticalsAtea Pharmaceuticals, Inc.
Mar 16, 202110,946,0332′-substituted-N6-substituted purine nucleotides for RNA virus treatmentPharmaceuticalsAtea Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 11, 20252025/0281520ADVANTAGEOUS ANTI-HCV COMBINATION THERAPYPharmaceuticalsAtea Pharmaceuticals, Inc. · patent 12,458,656 granted from it
Jul 31, 20252025/0243235Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTOrganic fine chemistryAtea Pharmaceuticals, Inc.
Apr 3, 20252025/0109163NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUSPharmaceuticalsAtea Pharmaceuticals, Inc.
Mar 13, 20252025/0082656DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTIONPharmaceuticalsAtea Pharmaceuticals, Inc.
Aug 8, 20242024/0261316HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc.
Jul 18, 20242024/0238324HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19PharmaceuticalsAtea Pharmaceuticals, Inc. · patent 12,226,429 granted from it
Jul 11, 20242024/02261312'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENTPharmaceuticalsAtea Pharmaceuticals, Inc.
May 9, 20242024/0148770ADVANTAGEOUS ANTI-HCV COMBINATION THERAPYPharmaceuticalsAtea Pharmaceuticals, Inc.
Jan 18, 20242024/0018179NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUSPharmaceuticalsAtea Pharmaceuticals, Inc. · patent 12,006,340 granted from it
Jan 4, 20242024/0002426BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTOrganic fine chemistryAtea Pharmaceuticals, Inc. · patent 12,084,473 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AVIR · research, not advice